Active surveillance for patients with prostate cancer aged ≥75 years: the Prostate Cancer Research International: Active Surveillance ( PRIAS) ‐ JAPAN study
A multicentre cohort study investigates clinical outcomes of active surveillance in older men with prostate cancer, suggesting effective monitoring can prevent overtreatment.
Key Points
To assess treatment outcomes and survival rates of men aged 75 years and older with prostate cancer in Japan.
Nationwide multicentre prospective cohort study
Inclusion of men with clinically localized prostate cancer
Monitoring PSA levels every 3–6 months
Comparing older patients (≥75 years) with younger ones (<75 years)
231 patients aged ≥75 years were enrolled out of 1274 total patients.
Older patients had larger prostate volumes and higher Gleason scores than younger patients.
10-year active surveillance persistence rate was 8.8% in the older group.
Overall survival was significantly lower in the older group with a hazard ratio of 0.32.
Metastasis-free survival and cancer-specific survival rates were 100% for the older group.